document.getElementById('index-articles-list').innerHTML = `

A Decade of Data Protection for Innovative Drugs in Canada: Issues, Limitations, and Time for a Reassessment

加拿大创新药物的数据保护：十年的议题、局限性及重新评估时机

Megan Kendall,Declan Hamill

Biotechnology law report. 2016 Dec 1;35(6):259-267. DOI:10.1089/blr.2016.29030.mk

Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs)

创新药物倡议（IMI）案例研究分析揭示了早期公私合作模式（PPP）的真正附加价值

Hilde Stevens,Geertrui Van Overwalle,Bart Van Looy et al.

Biotechnology law report. 2015 Aug 1;34(4):153-165. DOI:10.1089/blr.2015.29008.hs

Do Biotech Patent Lawsuits Really "Overwhelmingly Lose?": A Response to Our Divided Patent System

生物技术专利诉讼真的是“惨败”吗？对“分裂的专利制度”的回应

Christopher M Holman

Biotechnology law report. 2015 Apr 1;34(2):59-67. DOI:10.1089/blr.2015.9993

FDA's Expedited Approval Mechanisms for New Drug Products

美国食品药品监督管理局新药产品加速审批机制

Erin E Kepplinger

Biotechnology law report. 2015 Feb 1;34(1):15-37. DOI:10.1089/blr.2015.9999

The History of Technology Assessment and Comparative Effectiveness Research for Drugs and Medical Devices and the Role of the Federal Government

美国联邦政府在药品和医疗器械的技术评估与比较疗效研究中的作用及技术评估与比较疗效研究的历史

Jennifer Wong

Biotechnology law report. 2014 Dec 1;33(6):221-248. DOI:10.1089/blr.2014.9967

`; document.getElementById('index-articles-more').href = `https://i.iikx.com/journal/0730-031X.html`; document.getElementById('index-articles-more').innerHTML='更多内容'; document.getElementById('index-articles-more').style="float:right;background:var(--primary-color);color:#fff;font-size:13px;border-radius:5px;padding:0px 10px;margin-right:5px;line-height:1.7"; document.getElementsByClassName('index-artcles')[0].style.display = 'block'; document.getElementById('showJournalIndexUrl').style.display = 'block'; document.querySelector('#showJournalIndexUrl a').href = `https://i.iikx.com/journal/0730-031X.html`;